Generic name: Romosozumab
Brand name: Evenity
Formulation: 105 mg solution for injection in a pre-filled pen
Market Authorisation holder: UCB Pharma Limited
Indication: treatment of severe osteoporosis in postmenopausal women at high risk of fracture
Dose: 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once a month for 12 months. It is recommended that patients begin antiresorptive therapy after completing treatment with romosozumab.
Cost: £427.75 for two pre-filled pens each containing 105 mg romosozumab
Classification: Prescription only medicine (POM) subject to additional monitoring (▼)
- Bone Diseases
- Health Care Quality
- and Evaluation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests None declared.
Provenance and peer review Written by the DTB team; externally peer reviewed.